A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease
暂无分享,去创建一个
C. Tebé | B. Clotet | L. Ruiz | J. Argimon | M. Farré | E. Ballana | A. Elizalde-Torrent | G. Flores-Mateo | J. Puig | J. Ara | Eva Riveira-Muñoz | O. Mitjà | J. Casabona | Laia Bertran | R. Vivanco-Hidalgo | J. Peñafiel | S. Sanz | N. Nadal | N. Prat | A. Sierra | G. Cuatrecasas | C. Velasco | Maria Ubals | Clara Suñer | Robert Fabregat | S. Narejos | Sergi Gavilán | M. Vall-Mayans | A. Sentís | A. Alemany | M. Corbacho-Monné | Camila G-Beiras | Carles Quiñones | J. Zamora | C. López | Ferran Ramírez-Viaplana | A. Forcada | E. Muntada | N. Riera-Martí | Maria Sarquella | A. Tobías | C. A. Pérez | Pol Admella | P. Laporte | J. Mitjà | M. Clua | P. Cañadas | Aroa N Gil-Ortega | Juliana Reyes- Urueña | C. Quiñones | E. Riveira-Muñoz
[1] X. Tang,et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.
[2] Emily G McDonald,et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.
[3] L. Kucirka,et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.
[4] P. Zimetbaum,et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[5] Yongsheng Wu,et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study , 2020, The Lancet Infectious Diseases.
[6] K. Kupferschmidt. WHO launches global megatrial of the four most promising coronavirus treatments , 2020 .
[7] Zhìhóng Hú,et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.
[8] Zhìhóng Hú,et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.
[9] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Jianjun Gao,et al. Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.
[11] P. Klepac,et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.
[12] Gengfu Xiao,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[13] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[14] L. Yang,et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak , 2020, bioRxiv.
[15] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.
[16] H. Nishiura,et al. Preliminary estimation of the basic reproduction number of Zika virus infection during Colombia epidemic, 2015-2016. , 2016, Travel medicine and infectious disease.
[17] A Donner,et al. Developments in cluster randomized trials and Statistics in Medicine , 2007, Statistics in medicine.
[18] D. Ashby,et al. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. , 2006, International journal of epidemiology.
[19] N. Seidah,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.
[20] John O'Quigley,et al. Proportional hazards models with frailties and random effects , 2002, Statistics in medicine.
[21] S Wacholder,et al. Binomial regression in GLIM: estimating risk ratios and risk differences. , 1986, American journal of epidemiology.